Search company, investor...

Predict your next investment

University of Oxford company logo
Academic/University
CONSUMER PRODUCTS & SERVICES | Education & Training (non-internet/mobile) / Colleges & Universities
ox.ac.uk

Investments

47

Partners & Customers

10

About University of Oxford

The University of Oxford is a collegiate research university in Oxford, England.

Headquarters Location

Wellington Square

Oxford, England, OX1 2JD,

United Kingdom

+44 1865 270000

Want to inform investors similar to University of Oxford about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Expert Collections containing University of Oxford

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find University of Oxford in 1 Expert Collection, including Synthetic Biology.

S

Synthetic Biology

382 items

Latest University of Oxford News

First-in-Human Clinical Data Shows SonoTran® is Safe and Well-Tolerated

Jan 23, 2023

First-in-Human Clinical Data Shows SonoTran® is Safe and Well-Tolerated Data presented at the European Symposium on Ultrasound Contrast Imaging also demonstrated consistent SonoTran® Particle activation Recruitment underway for Delivery and Efficacy cohorts of Phase 1/2a proof of concept study OXFORD, UK, January 23, 2023 / B3C newswire / -- OxSonics Therapeutics , a clinical-stage medtech company focused on transforming cancer treatment through SonoTran®, its proprietary ultrasound-based drug delivery platform, today announces that first-in-human clinical data demonstrated that SonoTran® is safe and well-tolerated, with consistent Particle activation observed and mapped using OxSonics’ proprietary “see-as-you-treat” technology. The clinical data was presented by Dr Jeffrey Rubasingham, an oncologist at Oxford University Hospitals NHS Trust, Churchill Hospital, and the background and pre-clinical research by Professor Coussios, Statutory Chair of Biomedical Engineering at the University of Oxford and Director of the Oxford Institute of Biomedical Engineering, at the 28th European Symposium on Ultrasound Contrast Imaging, 19-20 January 2023. The data is part of an ongoing Phase 1/2a multicentre clinical investigation funded by the National Institute for Health Research (NIHR), where SonoTran® is being evaluated in patients with metastatic colorectal cancer (mCRC). SonoTran® is in clinical development to enhance the delivery and improve the efficacy of oncology drugs, particularly targeted biological therapies that struggle to penetrate tumors. It combines innovative Particles that are independently co-administered with an anti-cancer drug, which are then activated by a novel ultrasound device at the tumor site, creating a localised pumping effect that increases the delivery and penetration of the drug throughout the tumor. Nine patients were enrolled in the Safety Cohort, of which the primary objective was to evaluate the safety and tolerability of SonoTran® at three different doses of Particles, (three patients per dose). SonoTran® was safe and well tolerated at all three dose levels, with no serious adverse events reported. Particle activation (i.e. the generation of the Particle expansion and collapse that causes the localised pumping effect) at each dose level was also assessed using the Company’s “see as you treat” passive acoustic mapping technology. Consistent Particle activation was observed and mapped at all three dose levels. Based on these results, the lowest Particle dose (200mg) was selected for use in the Delivery and Efficacy Cohorts of the study, which are now both recruiting patients. The Delivery Cohort will assess how much SonoTran® can enhance the delivery of cetuximab and irinotecan into tumors in resectable mCRC patients and the Efficacy Cohort will evaluate SonoTran®’s ability to enhance tumor reduction when combined with standard of care first-line treatment (cetuximab and FOLFIRI), compared with the standard of care alone. Dr Marianna Lalla, Chief Medical Officer, OxSonics, commented: “We are delighted by our first-in-human clinical data, in which we see that SonoTran® is safe and well tolerated in patients. Pre-clinical data has shown that SonoTran® increases the tumour penetration of drugs, leading to reduced tumor size and increased survival, and we look forward to seeing if this is replicated in the clinic in the Delivery and Efficacy Cohorts.” Jérôme Marzinski, Chief Executive Officer, OxSonics, commented: “This clinical data is an important milestone for OxSonics showing that SonoTran® is safe and well tolerated, as well as that the SonoTran® Particles were consistently activated at the lowest dose. We believe that this Particle activation will be able to translate to enhanced delivery of drugs into solid tumors and ultimately potentially transform cancer treatment.” For more information on how SonoTran® works, click here . Current oncology drugs are restricted by their poor ability to penetrate solid tumors. SonoTran® is being developed to provide a step-change in the therapeutic index of the drugs without the development costs or delays associated with drug reformulation. It combines Particles that are co-administered independently with an anti-cancer drug, and activated by a novel ultrasound device, creating a localised pumping effect that increases the delivery and penetration of the anti-cancer drug throughout the tumor. SonoTran® is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumor cancers. The approach has been specifically designed to fit seamlessly into existing oncology clinical workflows, and has the major advantage of enabling healthcare professionals to “see-as-they-treat” by providing visualisation on-screen and in real time. SonoTran® is currently being evaluated in a phase 1/2a proof of concept clinical study in patients with metastatic colorectal cancer with liver metastases. The SonoTran® drug delivery platform is based on ground-breaking technological advances, originally invented at the University of Oxford’s Institute of Biomedical Engineering. OxSonics is based in Oxford in the UK. About the phase 1/2a SonoTran® proof of concept clinical study SonoTran® is being evaluated in a phase 1/2a multicentre clinical investigation in patients with metastatic colorectal cancer (mCRC) funded by the National Institute for Health Research ( NIHR ). The clinical investigation includes three patient cohorts to evaluate: The safety of the SonoTran® Platform (“Safety Cohort”); SonoTran®’s ability to enhance the delivery of cetuximab and irinotecan into tumors in resectable mCRC patients (“Delivery Cohort”); and SonoTran®’s ability to enhance tumor response to standard of care first-line chemotherapy (cetuximab + FOLFIRI) in unresectable mCRC patients (“Efficacy Cohort”). Cohorts 1, 2 and 3 will recruit patients at the Oxford Cancer Centre, Churchill Hospital, Oxford University Hospitals (OUH) NHS Foundation Trust. Cohort 2 will additionally recruit patients at the Queen Elizabeth Hospital, Birmingham (UHB) NHS Foundation Trust. The coordinating investigator of the whole trial and the OUH site principal investigator is Professor Rachel Kerr (Department of Oncology, University of Oxford). Funding high quality, timely research that benefits the NHS, public health and social care; Investing in world-class expertise, facilities and a skilled delivery workforce to translate discoveries into improved treatments and services; Partnering with patients, service users, carers and communities, improving the relevance, quality and impact of our research; Attracting, training and supporting the best researchers to tackle complex health and social care challenges; Collaborating with other public funders, charities and industry to help shape a cohesive and globally competitive research system; Funding applied global health research and training to meet the needs of the poorest people in low and middle income countries. NIHR is funded by the Department of Health and Social Care. Its work in low and middle income countries is principally funded through UK Aid from the UK government. Keywords: Humans; Proof of Concept Study; Clinical Trials, Phase I as Topic; Irinotecan; Cetuximab; Colonic Neoplasms; Rectal Neoplasms; Ultrasonography; Ultrasonography, Interventional; Clinical Conference; Biomedical Technology; Biotechnology; UK Published by B3C newswire

University of Oxford Investments

47 Investments

University of Oxford has made 47 investments. Their latest investment was in Optellum as part of their Series A on September 9, 2022.

CBI Logo

University of Oxford Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/27/2022

Series A

Optellum

$14M

No

18

7/21/2022

Series A

Brill Power

$10.5M

Yes

2

4/28/2022

Series B

OMass Therapeutics

$100M

No

2

4/11/2022

Series B

Subscribe to see more

Subscribe to see more

10

1/26/2022

Series A - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/27/2022

7/21/2022

4/28/2022

4/11/2022

1/26/2022

Round

Series A

Series A

Series B

Series B

Series A - II

Company

Optellum

Brill Power

OMass Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$14M

$10.5M

$100M

$99M

New?

No

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

18

2

2

10

10

University of Oxford Partners & Customers

10 Partners and customers

University of Oxford has 10 strategic partners and customers. University of Oxford recently partnered with Pranaiya & Arthur Magoffin Foundation on December 12, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

12/15/2022

Partner

United Kingdom

Collaboration Between Pranaiya and Arthur Magoffin Foundation and the University of Oxford on Postpartum Depression

Pranaiya and Arthur is proud to announce a collaboration with the University of Oxford focused on postpartum depression and other perinatal mental health illnesses .

1

12/15/2022

Partner

United Kingdom

Oxford climate research excellence recognised by renewed Met Office partnership

Professor Tim Woollings in the Department of Physics , who chairs the Oxford partnership with the Met Office , said : ` We are delighted that our partnership with the Met Office is continuing and developing , and that the wider Met Office network is flourishing .

1

12/8/2022

Partner

Japan

Sosei Heptares Enters R&D Agreements with the University of Oxford and KU Leuven to Identify and Validate Key GPCRs Driving Gastrointestinal and Immune Disorders

We have established partnerships with some of the world 's leading pharmaceutical companies and multiple emerging technology companies , including AbbVie , AstraZeneca , Genentech , GSK , Kallyope , Neurocrine Biosciences , Novartis , Pfizer , Takeda and Verily .

1

10/19/2022

Partner

United Kingdom

Subscribe to see more

Subscribe to see more

10

8/23/2022

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

12/15/2022

12/15/2022

12/8/2022

10/19/2022

8/23/2022

Type

Partner

Partner

Partner

Partner

Partner

Business Partner

Country

United Kingdom

United Kingdom

Japan

United Kingdom

United States

News Snippet

Collaboration Between Pranaiya and Arthur Magoffin Foundation and the University of Oxford on Postpartum Depression

Pranaiya and Arthur is proud to announce a collaboration with the University of Oxford focused on postpartum depression and other perinatal mental health illnesses .

Oxford climate research excellence recognised by renewed Met Office partnership

Professor Tim Woollings in the Department of Physics , who chairs the Oxford partnership with the Met Office , said : ` We are delighted that our partnership with the Met Office is continuing and developing , and that the wider Met Office network is flourishing .

Sosei Heptares Enters R&D Agreements with the University of Oxford and KU Leuven to Identify and Validate Key GPCRs Driving Gastrointestinal and Immune Disorders

We have established partnerships with some of the world 's leading pharmaceutical companies and multiple emerging technology companies , including AbbVie , AstraZeneca , Genentech , GSK , Kallyope , Neurocrine Biosciences , Novartis , Pfizer , Takeda and Verily .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

University of Oxford Team

5 Team Members

University of Oxford has 5 team members, including , .

Name

Work History

Title

Status

Tianyou Xu

Founder

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Tianyou Xu

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Founder

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.